MARKET

TLIS

TLIS

Talis Biomedical Corp
NASDAQ
9.20
+0.19
+2.11%
Closed 17:47 04/24 EDT
OPEN
9.07
PREV CLOSE
9.01
HIGH
9.20
LOW
8.77
VOLUME
3.35K
TURNOVER
0
52 WEEK HIGH
9.32
52 WEEK LOW
4.350
MARKET CAP
16.76M
P/E (TTM)
-0.2697
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TLIS last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at TLIS last week (0408-0412)?
Weekly Report · 04/15 11:21
Talis Biomedical Secures Interim CFO Amidst Corporate Changes
TipRanks · 04/11 21:02
Weekly Report: what happened at TLIS last week (0401-0405)?
Weekly Report · 04/08 11:27
Weekly Report: what happened at TLIS last week (0325-0329)?
Weekly Report · 04/01 11:24
Talis Biomedical Corp: Notice of Effectiveness
Press release · 04/01 10:43
TLIS Stock Earnings: Talis Biomedical Reported Results for Q4 2023
Talis Biomedical just reported results for the fourth quarter of 2023. The company reported earnings per share of -$7.39. Talis Biomedical reported revenue of $195,000. The stock is down 2.7% in the last day.
Investorplace · 03/29 03:54
Talis Biomedical Q4 EPS $(7.39) Up From $(15.15) YoY, Sales $195.00K Down From $257.00K YoY
Talis Biomedical reported quarterly losses of $7.39 per share. The company reported $195.00 thousand in sales this quarter. This is a 24.12 percent decrease over sales of $257.00 million in the same period last year. The firm also reported a 51.22 percent increase in sales.
Benzinga · 03/29 03:28
More
About TLIS
Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.

Webull offers Talis Biomedical Corp stock information, including NASDAQ: TLIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLIS stock methods without spending real money on the virtual paper trading platform.